Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 554-563, May 2009

Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes

  • Koen van Besien

      Affiliations

    • University of Chicago Medical Center, Chicago, Illinois
    • Corresponding Author InformationCorrespondence and reprint requests to: Koen van Besien, MD, University of Chicago, Section of Hematology/Oncology Rm 1209, 5841 South Maryland Avenue, Chicago, IL, 60637.
    • ,
  • Jeanette Carreras

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Philip J. Bierman

      Affiliations

    • University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Brent R. Logan

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Arturo Molina

      Affiliations

    • Cougar Biotechnology, Los Angeles, California
    • ,
  • Roberta King

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minneapolis
    • ,
  • Gene Nelson

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minneapolis
    • ,
  • Joseph W. Fay

      Affiliations

    • Baylor University Medical Center, Dallas, Texas
    • ,
  • Richard E. Champlin

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Hillard M. Lazarus

      Affiliations

    • University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Julie M. Vose

      Affiliations

    • University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Parameswaran N. Hari

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin

Received 22 October 2008; accepted 14 January 2009. published online 09 March 2009.

Abstract 

We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

Key Words: Lymphoma, Unrelated donor, Myeloablative

 

 Financial disclosure: See Acknowledgments on page 561.

PII: S1083-8791(09)00055-X

doi:10.1016/j.bbmt.2009.01.012

Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 554-563, May 2009

Article Tools

* Image Usage & Resolution